Development of Machine Learning-Based Personalized Predictive Models for Early Detection of Hepatocellular Carcinoma in HBV-Related Cirrhosis Patients with Low Levels of Serum Alpha-Fetoprotein
Research Square
2023
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Background: The continuous increase in the incidence of HCC in China is an urgent issue, and early diagnosis and treatment are crucial. This study aims to create personalized predictive models by combining machine learning technology with demographic, medical history, and non-invasive biomarker data. These models will enhance the decision-making capabilities of clinical doctors for liver cell carcinoma (HCC) in HBV-related cirrhosis patients with low levels of serum alpha-fetoprotein (AFP). Methods: A total of 6,980 patients were included for further analysis treated between January 2012 and December 2018 were assessed. The laboratory test and clinical data before treatment were gathered. The significant risk factors were selected, and the relative risk of each variable affecting HCC diagnosis was calculated with machine learning and univariate regression analysis. Finally, in order to establish machine learning models, the data set was partitioned into a validation set (20%) and training set (80%) at random. Results:.This study identified 12 independent risk factors for HCC by using Gaussian naïve Bayes (GNB), extreme gradient boosting (XGBoost), random forest (RF), and least absolute shrinkage and selection operation (LASSO) regression models. Multivariate analysis showed that males, age >60 years, alkaline phosphate (ALP) >150 U/L, AFP >25 ng/mL, carcinoembryonic antigen (CEA) >5 ng/mL, and fibrinogen (Fbg) >4 g/L were risk factors, while hypertension, calcium <2.25 mmol/L, potassium ≤3.5 mmol/L, direct bilirubin (DB) >6.8 µmol/L, hemoglobin (HB) <110 g/L, and glutamic-pyruvic transaminase (GPT) >40 U/L were protective factors in HCC patients. Based on these factors, a nomogram was constructed and showed an area under the curve (AUC) of 0.746 (sensitivity=0.710, specificity=0.646), which was significantly higher than AFP AUC of 0.658 (sensitivity=0.462, specificity=0.766). Compared with several machine learning algorithms, XGBoost model had an AUC of 0.832 (sensitivity=0.745, specificity=0.766) and independent validation AUC of 0.829 (sensitivity=0.766, specificity=0.737), which performed the highest level in both the test set and the training set. Conclusions: The proposed XGBoost for classifying HCC in patients with HBV-related cirrhosis with low-level AFP demonstrated promising ability for individualized prediction of HCC cases.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know